Mustang Bio stock holds steady as investors watch pipeline and funding outlook

Published on 09/04/2026 at 11:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mustang Bio stock is trading quietly as of September 4, 2026, while investors focus on the company’s gene therapy pipeline and its recent funding moves in a challenging biotech market.

Flatlay mit Aktien-Zertifikat, ISIN-Karte DE0005403901, Fotoabzügen und Kameraobjektiv — CEWE Stiftung & Co. KGaA DE0005403901 Flatlay mit Aktien-Zertifikat, ISIN-Karte und Fotoprodukten auf Marmor, Illustration mit AI erstellt.

Mustang Bio stock (ISIN US62815P1003) is trading at a low single-digit level as of September 3, 2026, reflecting the cautious sentiment around early stage gene therapy names and the company’s ongoing search for strategic and funding options.

Market view on Mustang Bio

According to market data for Mustang Bio, the stock last closed around USD 1.90 on September 3, 2026, after a modest daily move that kept it within its recent trading range.

The same overview shows that Mustang Bio’s market capitalization now stands at only a few tens of millions of USD as of early September 2026, underlining how far the valuation has fallen from the levels seen before the broader biotech correction.

Recent fundamentals in context

Financial portals summarizing Mustang Bio’s latest available annual report indicate that in fiscal year 2024 the company generated low single digit millions of USD in revenue while reporting a significantly larger net loss, highlighting the typical profile of a clinical stage biotech focused on developing gene therapies.

The same summaries state that research and development expenses for Mustang Bio in fiscal year 2024 were a multiple of its revenue, underscoring how heavily the business model depends on external capital and future potential milestone or licensing payments rather than current product sales.

Go deeper

Background on Mustang Bio stock

Investors can find more details on Mustang Bio’s equity story, filings and news by visiting the dedicated topic page and the company’s own investor information.

All news on Mustang Bio Investor Relations

Gene therapy focus and key product

Mustang Bio’s strategy is built around developing gene and cell therapies for hematologic cancers and other serious diseases, with a particular emphasis on chimeric antigen receptor T cell candidates.

A representative program is its CD19 targeted CAR T cell therapy, which aims to offer new treatment options for patients with relapsed or refractory leukemia and lymphoma and is a central element in how investors assess the long term potential of Mustang Bio’s pipeline.

Stock level and investor perspective

With Mustang Bio stock around USD 1.90 as of the close on September 3, 2026, and a very small market capitalization, the shares remain highly sensitive to any news on trial progress, partnerships or fresh financing rounds, which can quickly change the risk reward profile for retail investors.